CompletedNCT03403790
Official study titleDrug Use-results Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including AichiBipolarity, DepressionObservational study
- Countries
- Japan
- Sponsor
- Astellas Pharma Inc
CompletedNCT03809325
Official study titleCross-sectional Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
This study has finished and is no longer accepting participants.
Multiple locations, including BrusselsSchizophreniaObservational studyAges 18+
- Countries
- France, United Kingdom, Belgium, + 4 others
- Sponsor
- Janssen-Cilag International NV
CompletedNCT02667158
Official study titleA Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
This study has finished and is no longer accepting participants.
Location not clearly listedAddictionObservational studyAges 18+
- Countries
- Sponsor
- Member Companies of the Opioid PMR Consortium
CompletedNCT00232687
About this title
A Switch Study of BMS-337039 in Schizophrenic Out-patients
Read the official source — NCT00232687Official study titleA Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone
This study has finished and is no longer accepting participants.
Multiple locations, including Hall in TirolSchizophreniaMedication studyAges 18–65
- Countries
- France, United Kingdom, Belgium, + 7 others
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
CompletedNCT02183844
Official study titleImplementing Patient-Centered Decision Support for Mental Health
This study has finished and is no longer accepting participants.
In Los AngelesSchizophreniaBehavioural studyAges 18+
- Countries
- United States
- Sponsor
- University of California, Los Angeles
CompletedNCT03104504
Official study titleA System of Safety: Preventing Suicided Through Healthcare System Transformation
This study has finished and is no longer accepting participants.
In WorcesterSuicidalityBehavioural studyAges 12+
- Countries
- United States
- Sponsor
- University of Massachusetts, Worcester
CompletedNCT05588713
Official study titleA Systematic Study of ADHD Assessments Within Child and Adolescent Psychiatric Care
This study has finished and is no longer accepting participants.
In UppsalaADHDInterventional studyAges 8–17
- Countries
- Sweden
- Sponsor
- Uppsala University
Active Not RecruitingNCT06025435
Official study titleSAIA-SSP-HIV: a Systems Analysis and Improvement Approach to Optimizing HIV Service Delivery in Syringe Services Programs
This study is no longer accepting new participants.
In San DiegoMental healthInterventional studyAges 18+
- Countries
- United States
- Sponsor
- University of California, San Diego
CompletedNCT04502186
This study has finished and is no longer accepting participants.
Multiple locations, including HillsdaleDepressionBehavioural studyAges 18+
- Countries
- United States
- Sponsor
- University of Michigan
CompletedNCT05931432
This study has finished and is no longer accepting participants.
In PhiladelphiaAnxiety, DepressionInterventional studyAges 18+
- Countries
- United States
- Sponsor
- University of Pennsylvania
CompletedNCT02922959
This study has finished and is no longer accepting participants.
In CincinnatiAddictionMedication studyAges 18+
- Countries
- United States
- Sponsor
- University of Cincinnati
TerminatedNCT02566759
Official study titleA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects
This study ended early.
In LondonSchizophreniaMedication studyAges 18–55
- Countries
- United Kingdom
- Sponsor
- Neurocrine Biosciences (Biotech company)